Top

Published in:

01-04-2009 | Original Article

Protective Effect of Morin on Dimethylnitrosamine-Induced Hepatic Fibrosis in Rats

Authors: Hee-Seung Lee, Kyung Hee Jung, In-Suh Park, Sung Won Kwon, Don-Haeng Lee, Soon-Sun Hong

Published in: Digestive Diseases and Sciences | Issue 4/2009

Abstract

Morin, a plant-derived flavonoid, has been reported to exhibit a wide range of pharmacological properties. In this study, we investigated the protective effect of morin on hepatic fibrosis induced by dimethylnitrosamine (DMN) in rats. Oral administration of morin remarkably prevented weight loss in the body and liver from DMN and inhibited the elevation of serum alanine transaminase (ALT), aspartate transaminase (AST), and total bilirubin levels. For the evaluation of hepatic fibrosis-related factors, we investigated expressions of collagen type I, transforming growth factor β₁ (TGF-β₁), and α-smooth muscle actin (α-SMA) in mRNA and protein levels. We observed that morin significantly reduced the expression of collagen type I, TGF-β₁, and α-SMA on hepatic fibrosis induced by DMN. Taken together, this study demonstrated that morin showed hepatoprotective and antifibrogenic effects against DMN-induced hepatic injury. This suggests that morin may be useful in preventing the development of hepatic fibrosis and cirrhosis.

Wijeratne SS, Abou-Zaid MM, Shahidi F (2006) Antioxidant polyphenols in almond and its coproducts. J Agric Food Chem 54:312–318. doi:10.1021/jf051692j PubMedCrossRef

Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397–1421. doi:10.1016/j.bcp.2006.02.009 PubMedCrossRef

Xie MX, Long M, Liu Y, Qin C, Wang YD (2006) Characterization of the interaction between human serum albumin and morin. Biochim Biophys Acta 1760:1184–1191PubMed

Wu TW, Zeng LH, Wu J, Fung KP (1993) Morin hydrate is a plant-derived and antioxidant-based hepatoprotector. Life Sci 53:PL213–PL218. doi:10.1016/0024-3205(93)90266-6 PubMedCrossRef

Wu TW, Zeng LH, Wu J, Fung KP (1994) Morin: a wood pigment that protects three types of human cells in the cardiovascular system against oxyradical damage. Biochem Pharmacol 47:1099–1103. doi:10.1016/0006-2952(94)90424-3 PubMedCrossRef

Yu Z, Fong WP, CH Cheng (2006) The dual actions of morin (3, 5, 7, 2′, 4′-pentahydroxyflavone) as a hypouricemic agent. Uricosuric effect and xanthine oxidase inhibitory activity. J Pharmacol Exp Ther 316:169–175. doi:10.1124/jpet.105.092684 PubMedCrossRef

Kuo HM, Chang LS, Lin YL, Lu HF, Yang JS, Lee JH et al (2007) Morin inhibits the growth of human leukemia hl-60 cells via cell cycle arrest and induction of apoptosis through mitochondria dependent pathway. Anticancer Res 27:395–405PubMed

Manna SK, Aggarwal RS, Sethi G, Aggarwal BB, Ramesh GT (2007) Morin (3, 5, 7, 2′, 4′-pentahydroxyflavone) abolishes nuclear factor-kappab activation induced by various carcinogens and inflammatory stimuli, leading to suppression of nuclear factor-kappab-regulated gene expression and up-regulation of apoptosis. Clin Cancer Res 13:2290–2297. doi:10.1158/1078-0432.CCR-06-2394 PubMedCrossRef

Laughton MJ, Evans PJ, Moroney MA, Hoult JR, Halliwell B (1991) Inhibition of mammalian 5-lipoxygenase and cyclo-oxygenase by flavonoids and phenolic dietary additives. Relationship to antioxidant activity and to iron ion-reducing ability. Biochem Pharmacol 42:1673–1681. doi:10.1016/0006-2952(91)90501-U PubMedCrossRef

10.

Kawabata K, Tanaka T, Honjo S, Kakumoto M, Hara A, Makita H et al (1999) Chemopreventive effect of dietary flavonoid morin on chemically induced rat tongue carcinogenesis. Int J Cancer 83:381–386. doi:10.1002/(SICI)1097-0215(19991029)83:3<381::AID-IJC14>3.0.CO;2-XPubMedCrossRef

11.

Hsiang CY, Wu SL, Ho TY (2005) Morin inhibits 12-o-tetradecanoylphorbol-13-acetate-induced hepatocellular transformation via activator protein 1 signaling pathway and cell cycle progression. Biochem Pharmacol 69:1603–1611. doi:10.1016/j.bcp.2005.03.008 PubMedCrossRef

12.

Friedman SL (2003) Liver fibrosis—from bench to bedside. J Hepatol 38(Suppl 1):S38–S53. doi:10.1016/S0168-8278(02)00429-4 PubMedCrossRef

13.

Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209–218PubMed

14.

Pinzani M, Marra F (2001) Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 21:397–416. doi:10.1055/s-2001-17554 PubMedCrossRef

15.

Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A (2005) Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 45:605–628. doi:10.1146/annurev.pharmtox.45.120403.095906 PubMedCrossRef

16.

Yamazaki H, Inui Y, Yun CH, Guengerich FP, Shimada T (1992) Cytochrome p450 2e1 and 2a6 enzymes as major catalysts for metabolic activation of n-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13:1789–1794. doi:10.1093/carcin/13.10.1789 PubMedCrossRef

17.

Bertelli AA, Giovannini L, Stradi R, Bertelli A, Tillement JP (1996) Plasma, urine and tissue levels of trans- and cis-resveratrol (3, 4′, 5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int J Tissue React 18:67–71PubMed

18.

Lee MH, Yoon S, Moon JO (2004) The flavonoid naringenin inhibits dimethylnitrosamine-induced liver damage in rats. Biol Pharm Bull 27:72–76. doi:10.1248/bpb.27.72 PubMedCrossRef

19.

Ala-Kokko L, Pihlajaniemi T, Myers JC, Kivirikko KI, Savolainen ER (1987) Gene expression of type i, iii and iv collagens in hepatic fibrosis induced by dimethylnitrosamine in the rat. Biochem J 244:75–79PubMed

20.

Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H et al (1998) Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 28:439–446. doi:10.1016/S0168-8278(98)80318-8 PubMedCrossRef

21.

Aleynik SI, Leo MA, Ma X, Aleynik MK, Lieber CS (1997) Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis. J Hepatol 27:554–561. doi:10.1016/S0168-8278(97)80361-3 PubMedCrossRef

22.

Savolainen ER, Brocks D, Ala-Kokko L, Kivirikko KI (1988) Serum concentrations of the n-terminal propeptide of type iii procollagen and two type iv collagen fragments and gene expression of the respective collagen types in liver in rats with dimethylnitrosamine-induced hepatic fibrosis. Biochem J 249:753–757PubMed

23.

Jenkins SA, Grandison A, Baxter JN, Day DW, Taylor I, Shields R (1985) A dimethylnitrosamine-induced model of cirrhosis and portal hypertension in the rat. J Hepatol 1:489–499. doi:10.1016/S0168-8278(85)80747-9 PubMedCrossRef

24.

Bauer M, Schuppan D (2001) TGFbeta1 in liver fibrosis Time to change paradigms? FEBS Lett 502:1–3. doi:10.1016/S0014-5793(01)02655-2 PubMedCrossRef

25.

Giannelli G, Antonaci S (2005) Immunological and molecular aspects of liver fibrosis in chronic hepatitis C virus infection. Histol Histopathol 20:939–944PubMed

26.

Wells RG (2005) The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol 39:S158–S161. doi:10.1097/01.mcg.0000155516.02468.0f PubMedCrossRef

27.

Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA (2001) The role of smad3 in mediating mouse hepatic stellate cell activation. Hepatology 34:89–100. doi:10.1053/jhep.2001.25349 PubMedCrossRef

28.

Gressner AM, Weiskirchen R, Breitkopf K, Dooley S (2002) Roles of TGF-beta in hepatic fibrosis. Front Biosci 7:d793–d807. doi:10.2741/gressner PubMedCrossRef

Title: Protective Effect of Morin on Dimethylnitrosamine-Induced Hepatic Fibrosis in Rats
Authors: Hee-Seung Lee
Kyung Hee Jung
In-Suh Park
Sung Won Kwon
Don-Haeng Lee
Soon-Sun Hong
Publication date: 01-04-2009
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 4/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-008-0404-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

Protective Effects of Caffeic Acid Phenethyl Ester on Intestinal Ischemia-Reperfusion Injury

Decreased Total Antioxidant Capacity in Plasma, but Not Tissue, in Experimental Colitis

HFE Gene Mutations, Serum Ferritin Level, Transferrin Saturation, and Their Clinical Correlates in a Korean Population

Liver Transplantation for Hepatocellular Carcinoma in the MELD Era: Leading Roles of MELD Score, AFP Level, and Recipient Age as Predictors of Survival

Hemodynamic Studies in Acute-on-Chronic Liver Failure

Fasting Exacerbates and Feeding Diminishes LPS-Induced Liver Injury in the Rat

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials